~~<i id='05F4811B7D'><strike id='05F4811B7D'><tt id='05F4811B7D'><pre id='05F4811B7D'></pre></tt></strike></i>~~

Home» leisure time» Wikipedia

Wikipedia

author：explore 2025-09-12 19:44:40 Page View：7242

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Takeaways from AdvaMed, the largest medical devices conference
Next article： Anesthesiologist group: stop taking Ozempic before surgery

knowledge

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

What the Wegovy shortage looks like for doctors — and for patients

Afterphysicallydebilitatingcancertreatment,LaurieBrunnerencounteredanothermedicalhurdle:Shehaddevelo

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Life sciences deals on track to hit lowest point since 2017

AdobeIt’snosecretthatbiotechindustryfundinghasfallenfromitsCovidhighs.Butwithjustafewmonthsleftinthe